Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!

Masui, Kenichi

doi:10.1007/s00540-020-02755-1

Cited by 93 publications

(71 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remimazolam, a new ultrashort-acting GABA A receptor agonist, was approved for induction and maintenance of general anesthesia in adults, on January 23, 2020 in Japan [10,11]. In addition, it was approved by the US Food and Drug Administration, on July 3, 2020, for injection to achieve induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 min or less, and by the Chinese National Medical Products Administration, on July 20, 2020, for use in procedural sedation.…”

Section: Introductionmentioning

confidence: 99%

Sedation outcomes for remimazolam, a new benzodiazepine

et al. 2021

View full text Add to dashboard Cite

Remimazolam is a new ultrashort-acting benzodiazepine with fast onset, quick recovery, and few side effects, such as hypotension and respiratory depression. It is expected to be safe and effective for a wide range of patients undergoing intravenous sedation for dental procedures. The aim of this literature review was to evaluate clinical and sedation outcomes for remimazolam, including method of administration, level of sedation at the dose required, and clinical adverse events. An electronic literature search of databases was conducted, and eight articles were selected for inclusion in this review. Onset time from drug administration to optimal sedation level was faster for remimazolam (around 1.5-6.4 min) than for midazolam. Recovery time was significantly shorter for remimazolam than for midazolam and propofol. A study comparing various doses of remimazolam with midazolam found no significant difference in safety. Comparison of a remimazolam group with a propofol group showed that incidences of hypotension (13.0% vs 42.9%, respectively) and respiratory depression (1.1% vs 6.9%, respectively) were significantly lower for remimazolam. Remimazolam appears to be an ideal sedative.

show abstract

Section: Introductionmentioning

confidence: 99%

Sedation outcomes for remimazolam, a new benzodiazepine

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Remimazolam, a novel ultrashort-acting benzodiazepine, is now available for general anesthesia in Japan; it is expected to achieve more appropriate anesthesia induction and recovery compared to existing intravenous and volatile anesthetics [1,2].…”

Section: To the Editormentioning

confidence: 99%

How to administer remimazolam for anesthesia induction

2020

View full text Add to dashboard Cite

“…Remimazolam is a novel benzodiazepine that was approved as a general anesthetic in Japan [4]. Remimazolam is rapidly hydrolyzed and metabolized primarily by carboxylesterase in the liver.…”

Section: Introductionmentioning

confidence: 99%

Anesthetic management for a patient with myotonic dystrophy with remimazolam

2021

View full text Add to dashboard Cite

Background Patients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam. Case presentation The patient was a 46-year-old man, 169 cm in height, and weighing 60 kg. He was diagnosed with myotonic dystrophy 5 years previously. Phacoemulsification for both eyes was scheduled under general anesthesia. Anesthesia was induced with remimazolam 6 mg/kg/h for 1 min and maintained by continuous infusion at 0.25 mg/kg/h during surgery, a 1/4 dose of the standard infusion rate, as indexed by a bispectral index (BIS). Six minutes after remimazolam discontinuation, the patient opened his eyes on verbal command with sufficient spontaneous respiration. Flumazenil (0.2 mg) was administered to boost the patient’s recovery. Conclusion In addition to the short-acting anesthetic remimazolam, the presence of the antagonist flumazenil enabled complete recovery from anesthesia, without postoperative complications.

show abstract

Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!

Cited by 93 publications

References 35 publications

Sedation outcomes for remimazolam, a new benzodiazepine

Sedation outcomes for remimazolam, a new benzodiazepine

How to administer remimazolam for anesthesia induction

Anesthetic management for a patient with myotonic dystrophy with remimazolam

Contact Info

Product

Resources

About